Research Analysts Set Expectations for PLX FY2025 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities researchers at Zacks Small Cap dropped their FY2025 EPS estimates for Protalix BioTherapeutics in a research note issued on Monday, February 3rd. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will earn $0.44 per share for the year, down from their previous estimate of $0.63. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. Zacks Small Cap also issued estimates for Protalix BioTherapeutics’ FY2026 earnings at $0.84 EPS.

Several other brokerages also recently commented on PLX. HC Wainwright increased their target price on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday. StockNews.com cut Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday.

Protalix BioTherapeutics Stock Up 6.0 %

Shares of PLX opened at $2.67 on Wednesday. Protalix BioTherapeutics has a twelve month low of $0.82 and a twelve month high of $2.71. The company has a market capitalization of $196.59 million, a P/E ratio of -20.54 and a beta of 0.75. The firm has a 50 day moving average of $2.01 and a 200 day moving average of $1.43.

Institutional Investors Weigh In On Protalix BioTherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd purchased a new position in shares of Protalix BioTherapeutics in the 4th quarter worth $35,000. XTX Topco Ltd purchased a new position in Protalix BioTherapeutics in the third quarter worth about $36,000. Cubist Systematic Strategies LLC purchased a new position in Protalix BioTherapeutics in the second quarter worth about $37,000. Sanctuary Advisors LLC bought a new stake in shares of Protalix BioTherapeutics during the 3rd quarter valued at about $38,000. Finally, PFG Investments LLC purchased a new stake in shares of Protalix BioTherapeutics during the 4th quarter valued at about $39,000. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.